Mizuho has significantly reduced its price target for UnitedHealth Group (UNH) from $430 to $350 following the company's fourth-quarter results. Despite the substantial downward revision, the financial institution maintained its 'Outperform' rating on the stock, indicating long-term potential. The adjustment reflects a slower-than-anticipated recovery in earnings and ongoing uncertainty regarding the healthcare landscape. While the company reported a 12% revenue growth in 2025 driven by its Medicare and retirement business, regulatory headwinds remain a primary concern. Analysts are particularly focused on potential policy shifts under the Trump administration that could impact Medicare Advantage reimbursement rates. This combination of sluggish earnings momentum and regulatory risks has prompted a more cautious valuation of the healthcare giant.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis